Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Oxford BioMedica PLC - Oxford, England-based gene and cell therapy company - Expands its license and clinical supply agreement with Juno Therapeutics Inc, subsidiary of New-York based pharmaceutical industry company Bristol Myers Squibb. It says the expansion relates to the start of two new viral vector programmes for CAR-T therapies. ‘Oxford Biomedica will receive an undisclosed target nomination fee and potential payments upon the achievement of certain milestones,’ it notes.
Interim Chief Executive Officer Roch Doliveux says: ‘Bristol Myers Squibb is a strategically important partner to Oxford Biomedica and we are pleased to announce this expansion of our License & Clinical Supply Agreement. BMS is a proven commercial and clinical leader in the CAR-T field and we are pleased to announce the initiation of the two new programmes, taking the number of programmes we are working on with BMS to six.’
CAR-T - chimeric antigen receptor T-cell therapy involves reprogramming the patient's own immune system cells to target their cancer.
Current stock price: 487.50 pence, up 3.2%
12-month change: down 63%
Copyright 2022 Alliance News Limited. All Rights Reserved.